Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide

Vaccine

Volumn 26, Issue 23, 2008, Pages 2925-2929

  Csordas, Fátima C L ^a   Perciani, Cátia T ^a   Darrieux, Michelle ^a   Gonçalves, Viviane M ^a   Cabrera Crespo, Joaquim ^a   Takagi, Mickie ^a   Sbrogio Almeida, Maria E ^a   Leite, Luciana C C ^a   Tanizaki, Martha M ^a  

^a INSTITUTO BUTANTAN   (Brazil)

Author keywords

Capsular polysaccharide 23F; Conjugate vaccine; PspA

Indexed keywords

ALUMINUM HYDROXIDE; ANTIINFECTIVE AGENT; BACTERIAL POLYSACCHARIDE; PNEUMOCOCCAL SURFACE PROTEIN A;

ANTIBODY PRODUCTION; ARTICLE; BACTERIAL INFECTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; STREPTOCOCCUS PNEUMONIAE; SURVIVAL;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MICE; MICE, INBRED BALB C; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

EID: 43249131848     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.038     Document Type: Article

References (31)

1. Musher D.M. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity and treatment. Clin Infect Dis 14 (1991) 801-807
2. Lynch J.P., and Zhanel G.G. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implication for therapy. Semin Respir Crit Care Med 26 (2005) 575-616
3. Klein D.L., and Ellis R.W. Conjugate vaccines against Streptococcus pneumoniae. In: Levine M.M., Woodrow G.C., Kaper J.B., and Cobon G.S. (Eds). New Generation Vaccines. 2nd ed. (1997), Marcel Dekker, Inc., New York 503-525
4. Mosier D.D., and Subbarao B. Thymus independent antigens: complexity of B lymphocyte activation revealed. Immunol Today 3 (1982) 217-225
5. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurtburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal vaccine coverage. JAMA 297 (2007) 1784-1792
6. Paton J.C. New pneumococcal vaccines: basic science developments. In: Tuomanen E.I., Mitchell T.J., Morrison D.A., and Spratt B.G. (Eds). The Pneumococcus (2004), ASM Press, Washington, DC p. 382-402
7. Tu A.H.T., Fulgman R.L., Mc Cory M.A., Briles D.E., and Szalai A.J. Pneumococcal surface protein A (PspA) inhibits complement activation by Streptococcus pneumonia. Infect Immunol 67 (1999) 4720-4724
8. Mirza S., Hollinghead S.K., Willian Jr. J.H., and Briles D.E. PspA protects Streptococcus pneumoniae from killing by apolactoferrin and antibody to PspA enhances killingby apolactoferrin. Infect Immunol 72 (2004) 5031-5040
9. Briles D.E., Hollingshead S.K., King J., Swft A., Braun P.A., Park M.K., et al. Immunization of humans with rPspA elicits antibodies which passively protect mice from fatal infection with Streptococcus pneumonia bearing heterologous PspA. J Infect Dis 182 (2000) 1694-1701
10. Khan A.K., Lees A., and Snapper C.M. Differential regulation of anti-capsular polysaccharide and antiprotein responses to intact Streptococcus pneumonia in the presence of cognate CD4+ Tcell help. J Immunol 172 (2004) 532-539
11. Sen G., Chen Q., and Snapper C.M. Immunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpGp-containing oligodeoxynucleotide receptors defective immunoglobulin G antipolysaccharide responses and specific CD4+-T-cell priming to young adult levels. Infect Immunol 74 (2006) 2177-2186
12. Michon F., Fusco P.C., Minetti C.A.S.A., Laude-Sharp M., Moore S., Remeta D.P., et al. Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein. Vaccine 16 (1998) 1732-1741
13. Lee C.J., Wang T.R., and Frasch C.E. Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers. Vaccine 19 (2001) 3216-3225
14. Gonçalves V.M., Zangirolami T.C., Giordano R.C., Raw I., Tanizaki M.M., and Giordano R.C. Optimization of medium and cultivation conditions for capsular polysaccharide production by Streptococcus pneumoniae serotype 23F. Appl Microbiol Biotechnol 59 (2000) 713-717
15. Gonçalves V.M., Takagi M., Lima R.B., Massaldi H., Giordano R.C., and Tanizaki M.M. Purification of capsular polysaccharide from Streptococcus pneumoniae serotype 23F by a procedure suitable for scale-up. Biotechnol Appl Biochem 37 (2003) 283-287
16. Silva M., Cabrera-Crespo J., Sbrogio-Almeida M.E., Miyaji E.N., Ho P.L., and Leite L.C.C. Lopes APY. Optimizing expression of Streptococcus pneumoniae surface protein A, PspA: serocross-reactivity within families of antisera induced against clades 1 and 3. Mol Biotechnol 37 (2007) 146-154
17. Dische Z., and Shettles L.B.A. A specific color reaction methylpentoses and a spectrophotometric micromethod for their determination. J Biol Chem 175 (1948) 595-603
18. Qi X.Y., Keyhani N.O., and Lee Y.C. Spectrophotometric determination of hydrazine, hydrazide and their mixture with trinitrobenzene sulfonic acid. Anal Biochem 175 (1988) 139-144
19. Fukasawa L.O., Gorla M.C.O., Schenkman R.P.F., Garcia L.R., Carneiro S.M., and Raw I. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Vaccine 17 (1999) 2951-2958
20. Perciani C.T., Peixoto P.S., Dias W.O., Kubrusly F.S., and Tanizaki M.M. Improved method to calculate the antibody avidity index. J Clin Lab Anal 21 (2007) 201-206
21. Ren B., Szalai A.J., Hollingshead S.K., and Briles D.E. Effect of PspA antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immunol 72 (2004) 114-122
22. Sanz-Moreno J.C., Limia-Sanchez A., Garcia-Comas L., Mosquera-Gutierrez M.M., Echevarria-Mayo J.E., Castellanos-Nadal A., et al. Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G. Vaccine 23 (2005) 4921-4925
23. Poolman J.T. Polysaccharides and membrane vaccines. In: Mizrahi A. (Ed). Advances in biotechnological processes, vol. 13 (1990), Wiley-Liss, New York 58-86
24. Pawlowski A., Kallenius G., and Svenson S.V. Preparation of pneumococcal capsular polysaccharide protein conjugate vaccines utilizing new fragmentation and conjugation technologies. Vaccine 18 (2000) 1873-1885
25. de Velasco E.A., Verheul A.F.M., van Stejn A.M.P., Dekker H.A.T., Feldman R.G., Fernandez I.M., et al. Epitope specificity of rabbito immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide and native PS-protein conjugate vaccine: comparison with human anti-PS23F IgG. Infect Immunol 62 (1994) 799-808
26. Ahman H., Erikson K., Sörberg M., and Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 month of age. Pediatr Infect Dis 24 (2005) 108-114
27. Fukasawa L.O., Dias W.O., Schenkman P.F., Raw I., and Tanizaki M.M. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice. FEMS Immunol Med Microbiol 41 (2004) 205-210
28. Chackerian B., Lowy D.R., and Schiller J.T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108 (2001) 415-423
29. Brown J.S., Hussell T., Gilliland S.M., Holden D.W., Paton J.C., Ehrenstein M.R., et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci 99 (2002) 16969-16974
30. Ren B., McCrory M.A., Pass C., Bullard D.C., Ballantyne C.M., Xu Y., et al. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection. J Immunol 173 (2004) 7506-7512
31. Daniels C.C., Briles T.C., Mirza S., Hakansson A.P., and Briles D.E. Capsule does not block binding to PspA, a surface virulence protein of Streptococcus pneumoniae. Microbiol Path 40 (2006) 228-233